Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma.
نویسندگان
چکیده
278 Background: In clinical practice, the major disadvantage of lenvatinib to treat advanced hepatocellular carcinoma (HCC) is lack a posttreatment agent that has shown clear effectiveness. Thus, establishment second-line treatment after failure an urgent issue be addressed in systemic therapy patients with HCC. The study used real-world data explore candidate drugs might appropriate as lenvatinib. Methods: We retrospectively reviewed medical records all HCC who received first-line seven institutions Japan between 23 March 2018 and 31 September 2019. Results: During period, 178 therapy. At time administration, most were Eastern Cooperative Oncology Group Performance Status grade 0 or 1 (94.9%) Child–Pugh class A (84.3%). According baseline radiological assessments, 25.3% 36.0% had macrovascular invasion extrahepatic metastasis, respectively. Overall survival progression-free (PFS) for 13.3 months (95% CI: 11.5–15.2) 6.7 5.1–8.3), Of 151 discontinued lenvatinib, 71 (47.0%) converted posttreatment. conversion rates from third-line 41.4% 42.4%, Based on multivariate analysis, response was defined complete partial according modified Response Evaluation Criteria Solid Tumors (mRECIST). Lenvatinib discontinuation due progression, mRECIST, associated significantly higher probability 63 therapy, 53 (84.1%) administered sorafenib, PFS, rate (RR), disease control (DCR) 1.8 0.6–3.0), 1.8%, 20.8%, Cox proportional hazards regression model, B, intrahepatic tumor volume > 50% at sorafenib administration contributed shorter PFS. 22 regorafenib discontinuation, five cases 17 RR, DCR 3.2 (range, 1.5–4.9 months), 13.6%, 36.3%, Conclusions: Sorafenib not considered except limited number without progression. Regorafenib potential
منابع مشابه
Lenvatinib in Advanced Hepatocellular Carcinoma.
Sorafenib has been the standard therapy for patients with unresectable hepatocellular carcinoma (HCC) since 2007, when it was shown to prolong survival, as verified in the SHARP trial [1] and a study conducted in the Asia-Pacific region [2] . Since then, other molecular-targeted agents superior to sorafenib in efficacy or safety in the first-line treatment of HCC were developed and tested in cl...
متن کاملSafety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
PURPOSE To determine the maximum tolerable dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lenvatinib in patients with advanced hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN This multicenter, open-label, phase I, dose-escalation study included patients aged 20 to 80 years, refractory to standard therapy, and stratified by hepatic function measured usi...
متن کاملCancer Therapy: Clinical Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Purpose: To determine the maximum tolerable dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of lenvatinib in patients with advanced hepatocellular carcinoma (HCC). Experimental Design: This multicenter, open-label, phase I, dose-escalation study included patients aged 20 to 80 years, refractory to standard therapy, and stratified by hepatic function measured usi...
متن کاملLenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Management options are limited for patients with radioactive iodine refractory, locally advanced, or metastatic differentiated thyroid carcinoma. Prior to 2015, sorafenib, a multitargeted tyrosine kinase inhibitor, was the only approved treatment and was associated with a median progression-free survival (PFS) of 11 months and overall response rate (ORR) of 12% in a phase III trial. Lenvatinib,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Oncology
سال: 2021
ISSN: ['1527-7755', '0732-183X']
DOI: https://doi.org/10.1200/jco.2021.39.3_suppl.278